# About Reviews NAD: An Independent NAD+ Research Digest

> Reviews NAD is an independent editorial project that summarizes the peer-reviewed NAD+ research literature. Not a clinic, not a vendor — a cited digest of the published science.

An independent editorial reading of the NAD+ literature — opinionated about the evidence, scrupulous about the citations.

## What this site is

Reviews NAD is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ and its precursors. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The name carries the word 'reviews,' and that is exactly the register: we review the published evidence — the randomized precursor trials, the mechanism and aging literature, the recent meta-analyses — and report what each study actually measured. 'Reviews' here means the editorial act of weighing the research, never a storefront, an IV lounge, or a supplement shelf.

## How we read the evidence

Our editorial line is simple and consistent. When the controlled trials agree on something — that oral NR and NMN raise whole-blood NAD+ dose-dependently [4][3] — we say so plainly and at scale, because reproducibility across randomized trials is itself worth surfacing. When the evidence is thin or mixed — IV NAD+'s pilot-grade data [10], the unproven hard human endpoints [10], the NMN meta-analysis null on metabolic markers [14] — we mark the gap as clearly as the finding. We keep one distinction exact throughout: NAD+ is the coenzyme, NMN and NR are precursors, and a study that dosed a precursor is never described here as 'taking NAD+.'

## What the name does and does not mean

A word on framing. NAD+ is regulated as a dietary supplement, not an approved medicine, and nothing here implies otherwise. We describe research findings using study-attributed language and we give no dosing instructions and no medical recommendations. The editorial 'reviews' framing is a position this publisher occupies relative to the literature — a reader and a summarizer of it — not a claim about services, treatment, or commerce. Every number on the site is sourced; if a claim is not in the cited research, we do not make it. For the studies themselves, see the [full reference list](/references).

---

A billboard reading of the NAD+ record — the precursor trials that reliably raise blood NAD+ set in large type, the rapidly-cleared IV claims and the still-preliminary human endpoints qualified in the line beneath, the FDA injectable recall and the NMN-supplement dispute flagged in plain sight; no clinic behind the broadcast and nothing here infused, dosed, prescribed, or sold.